Researchers found that GLP-1 receptor agonists (GLP-1RAs) significantly reduce the risk of several blood cancers in type 2 ...

This study provides valuable guidance for doctors and patients when choosing diabetes medications. It confirms that ...

Telehealth company Hims & Hers Health (HIMS) witnessed a major dip in its stock recently despite reporting 95% revenue growth ...

Insurance coverage for GLP-1 drugs remains tight despite rising demand, with more patients facing restrictions or paying out ...

We recently published a list of 10 Best Weight Loss Drug Stocks to Buy According to Analysts. In this article, we are going ...

Biotechnology firm Biocon has announced the launch of its new product, Liraglutide, aimed at managing diabetes and obesity in the UK. This pivotal move was made public on Friday. The GLP-1 peptide, ...

Biopharmaceutical firm Biocon Ltd announced the launch of its Glucagon-like Peptide-1 (GLP-1) analog, Liraglutide, in the United Kingdom (U.K.). The drug is used for the treatment of diabetes and ...

Biocon announced the launch of its GLP-1 peptide, Liraglutide, for diabetes and obesity, in the United Kingdom (U.K.). The drug-device combination will be marketed in the U.K. under the brand names ...

Since, the patent for the diabetes drug Liraglutide has expired CTT will seek to find opportunities to utilize our micelle technology for Liraglutide. CTT also believes our technology could offer an ...

For 2025, revenue is expected in the range of $2.3B to $2.4B, which includes at least $725M from GLP-1 drugs such as compounded semaglutide and generic liraglutide. Analysts, on average ...

Hims plans to launch a generic version of liraglutide, but its efficacy is significantly lower than semaglutide and tirzepatide. Despite the setback, Hims shows strong financial health with 77% Y ...